ASTERIX: Low Dose ASA and Nexium
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00251966|
Recruitment Status : Completed
First Posted : November 11, 2005
Last Update Posted : March 12, 2009
|Condition or disease||Intervention/treatment||Phase|
|Gastroesophageal Reflux||Drug: Esomeprazole||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||960 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized Double-Blind Placebo-Controlled Study to Assess the Prevention of Low-Dose Acetylsalicylic Acid (ASA) Associated Gastroduodenal Lesions and Upper Gastrointestinal Symptoms in Patients Taking Esomeprazole 20 mg Once Daily for 26 Weeks.|
|Study Start Date :||May 2004|
|Actual Study Completion Date :||September 2005|
- The primary variable is presence of gastric and/or duodenal ulcers at endoscopy over a 26-week period in patients taking low-dose ASA.
- LA classification for the oesophagus at endoscopy. Upper GI symptoms assessed by the investigator at each study visit.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00251966
Show 93 Study Locations
|Study Director:||AstraZeneca Nexium Medical Science Director, MD||AstraZeneca|
|Principal Investigator:||Neville Yeomans, MD||Perth Medical School|